RxDoctor Payments Data

Donna Miller

Adult Health · Beverly Hills, CANPI 1427068204

Payments from drug & device makers

$727in general payments, 2019–2025

Across 26 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$193
  • Abbott$176
  • Insulet Corporation$169
  • Tandem Diabetes Care, Inc.$53
  • Dexcom, Inc.$53
  • Lilly USA, LLC$23
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$70397%
  • Education$233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$727 in reported general payments places this provider in the 60th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$42,043
Medicare patients
101
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide90$117,823
OzempicSemaglutide62$84,340
MounjaroTirzepatide63$78,917
Tresiba Flextouch U-100Insulin Degludec87$59,318
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/739$49,323
JardianceEmpagliflozin33$46,100
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$22,527
Tresiba Flextouch U-200Insulin Degludec12$16,735
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$9,635
BaqsimiGlucagon20$8,866
Nano 2nd Gen Pen NeedlePen Needle, Diabetic53$5,669
HumalogInsulin Lispro14$5,267
Novolog FlexpenInsulin Aspart22$3,305
LantusInsulin Glargine,hum.Rec.Anlog14$2,582
Humalog Junior KwikpenInsulin Lispro16$2,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog$23$210,874187 claims
Novo NordiskOzempic$193$84,34062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 785 adult health providers in California.

Other adult health in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →